Tenboron

Tenboron is a pioneering company in the field of Boron Neutron Capture Therapy (BNCT), focusing on developing novel boron carriers that target cancerous cells with high precision. The company operates in the healthcare and biotechnology market, serving medical institutions and research organizations that specialize in cancer treatment. Tenboron's business model revolves around the research, development, and commercialization of advanced boron carriers, which are critical for the efficacy of BNCT. The company generates revenue through partnerships, grants, and the sale of its proprietary boron carriers to healthcare providers and research institutions. Tenboron has received financial support from Tekes, the Finnish Funding Agency for Innovation, which underscores the potential and credibility of its technology. The company's boron carriers have shown superior results in preclinical tests, significantly outperforming existing solutions. With a robust synthesis route and successful pre-GMP production test runs, Tenboron is well-positioned to bring its innovative products to market. The benefits of BNCT include its potential to cure 15-20% of terminal phase patients, its applicability to various solid tumors, minimal impact on healthy tissues, cost-effectiveness, and the ability to be combined with other treatments. Tenboron's advancements in boron carrier technology aim to enhance these benefits, making BNCT a more viable and effective cancer treatment option.

Keywords: BNCT, boron carriers, cancer treatment, biotechnology, healthcare, targeted therapy, innovation, preclinical tests, Tekes funding, solid tumors.